Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 211 to 225 of 449 results for cardiovascular disease

  1. Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions (HTG492)

    Evidence-based recommendations on percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions. This involves inserting temporary pump to support circulation during a heart operation.

    HealthTech guidance
    Published
    28 November 2018
    View recommendations

    Sections for HTG492

  2. What is the effectivness of statin treatment in older people?

    Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid modification

    Research recommendation
    Published
    3 May 2024

  3. What is the effectivness of stains and/or other lipid-lowering treatment in people with type 1 diabetes?

    Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid modification

    Research recommendation
    Published
    3 May 2024

  4. Automated blood pressure monitoring in people with atrial fibrillation: Which automated blood pressure monitors are suitable for people with hypertension and atrial fibrillation?

    monitoring treatment and blood pressure targets for people without cardiovascular disease. Full details of the evidence and the...

    Research recommendation
    Published
    11 April 2022

  5. Blood pressure targets for people with aortic aneurysm: What are the optimal blood pressure targets in adults with hypertension and aortic aneurysm, and does this vary by age?

    the rationale and impact section on blood pressure targets for people with cardiovascular disease. Full details of the evidence and the...

    Research recommendation
    Published
    11 April 2022

  6. Blood pressure targets for people with prior ischaemic or haemorrhagic stroke: What are the optimal blood pressure targets in adults with prior ischaemic or haemorrhagic stroke, and does this vary by age?

    the rationale and impact section on blood pressure targets for people with cardiovascular disease. Full details of the evidence and the...

    Research recommendation
    Published
    11 April 2022

  7. Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)

    Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction.

    Technology appraisal guidance
    Published
    27 April 2016
    View recommendations

    Sections for TA388

  8. What is the effectiveness of age alone and other routinely available risk factors compared with the formal structured multifactorial risk assessment to identify people at high risk of developing CVD?

    . Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid modification

    Research recommendation
    Published
    3 May 2024

  9. What is the effectiveness of statins and/or other LDL-cholesterol-lowering treatment in people with type 1 diabetes?

    diabetes. Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid...

    Research recommendation
    Published
    9 June 2015

  10. Transcatheter endovascular closure of perimembranous ventricular septal defect (HTG213)

    Evidence-based recommendations on transcatheter endovascular closure of perimembranous ventricular septal defect. This involves inserting a small blocking device (called an occluder) into the heart.

    HealthTech guidance
    Published
    24 March 2010
    View recommendations

    Sections for HTG213

  11. Hearing loss in adults: assessment and management (NG98)

    This guideline covers some aspects of assessing and managing hearing loss in primary, community and secondary care. It aims to improve the quality of life for adults with hearing loss by advising healthcare staff on assessing hearing difficulties, managing earwax and referring people for audiological or specialist assessment and management.

    NICE guideline
    Last updated
    2 October 2023
    View recommendations

    Sections for NG98

  12. Schizophrenia: lurasidone (ESNM48)

    Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making

    Evidence summary
    Published
    23 September 2014

  13. What is the clinical effectiveness and rate of adverse events of statin therapy using atorvastatin 20 mg per day compared with atorvastatin 40 mg per day and atorvastatin 80 mg per day in people without established CVD?

    prevention of CVD and should be recommended for those at 10% risk of cardiovascular events as assessed using the QRISK2 calculator....

    Research recommendation
    Published
    9 June 2015

  14. Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)

    Evidence-based recommendations on guselkumab (Tremfya) for active psoriatic arthritis after inadequate response to DMARDs in adults.

    Technology appraisal guidance
    Published
    10 August 2022
    View recommendations

    Sections for TA815

  15. What is the improvement in the cost-effectiveness metrics for statin therapy in reducing CVD that can be obtained when using a complete individual patient-based outcomes meta-analysis data set compared with using published outcomes data?

    data. Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid modification

    Research recommendation
    Published
    9 June 2015